Last reviewed · How we verify

CSII, Metformin, Pioglitazone

Sun Yat-sen University · FDA-approved active Small molecule

This is a combination therapy using continuous subcutaneous insulin infusion (CSII) with metformin and pioglitazone to improve glycemic control through multiple pathways: insulin replacement, reduced hepatic glucose production, and enhanced insulin sensitivity.

This is a combination therapy using continuous subcutaneous insulin infusion (CSII) with metformin and pioglitazone to improve glycemic control through multiple pathways: insulin replacement, reduced hepatic glucose production, and enhanced insulin sensitivity. Used for Type 2 diabetes mellitus (marketed combination regimen).

At a glance

Generic nameCSII, Metformin, Pioglitazone
SponsorSun Yat-sen University
Drug classInsulin + biguanide + thiazolidinedione combination
TargetInsulin receptor (CSII); AMPK/mitochondrial function (metformin); PPAR-γ (pioglitazone)
ModalitySmall molecule
Therapeutic areaDiabetes
PhaseFDA-approved

Mechanism of action

CSII delivers rapid-acting insulin continuously and via boluses to replace endogenous insulin secretion. Metformin reduces hepatic gluconeogenesis and improves peripheral glucose uptake. Pioglitazone, a thiazolidinedione, enhances insulin sensitivity by activating PPAR-γ in adipose and muscle tissue. Together, these agents address multiple defects in type 2 diabetes pathophysiology.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: